The TGA Compliance Principles 2026 and 2027 provide a structured, risk-based framework for monitoring, enforcing, and supporting compliance with the Therapeutic Goods Act 1989.
By transforming chaos into control, businesses can leverage regulatory compliance as a tool for market differentiation, operational excellence, and sustainable growth
Investing in QSN’s capability-building approach transforms compliance from a temporary activity into a sustainable organisational strength, reinforcing quality culture, reducing risk, and enabling long-term operational excellence.
Regulatory complexity and compliance burden are inherent challenges in the therapeutic goods and biotechnology sectors. Startups must contend with fragmented, technical, and constantly evolving global and local regulatory requirements